Showing results (31-40 of 131) with videos related to

Sort By:
Pageof 14
Oncology Research|February 6, 2009
Gene therapy for malignant pleural mesothelioma: present and futureYuji Tada, Yuichi Takiguchi, Kenzo Hiroshima, et al.
Plos One|February 23, 2026
Strategic selection of MDM2 inhibitors enhances the efficacy of FAK inhibition in mesothelioma based on TP53 genotypeXuerao Ning, Thảo Thi Thanh Nguyễn, Takao Morinaga, et al.
Respiratory Medicine Case Reports|June 2, 2015
Pneumocystis pneumonia in everolimus therapy: An indistinguishable case from drug induced interstitial lung diseaseToshio Suzuki, Yuji Tada, Kenji Tsushima, et al.
Respiration; International Review of Thoracic Diseases|June 29, 2018
Efficacy of End-Tidal Capnography Monitoring during Flexible Bronchoscopy in Nonintubated Patients under Sedation: A Randomized Controlled StudyTsukasa Ishiwata, Kenji Tsushima, Jiro Terada, et al.
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|April 13, 2011
[A case of small-cell lung carcinoma accompanied by the syndrome of inappropriate secretion of antidiuretic hormone and Lambert-Eaton myasthenic syndrome]Takeshi Kobayashi, Takeru Watanabe, Hironori Ashinuma, et al.
Asia-Pacific Journal of Clinical Oncology|September 7, 2020
Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety studyTakashi Nakano, Kozo Kuribayashi, Masashi Kondo, et al.
Apoptosis : an International Journal on Programmed Cell Death|May 30, 2020
Combination of a p53-activating CP-31398 and an MDM2 or a FAK inhibitor produces growth suppressive effects in mesothelioma with wild-type p53 genotypeBoya Zhong, Masato Shingyoji, Michiko Hanazono, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 24, 2002
Cutting edge: a novel role for Fas ligand in facilitating antigen acquisition by dendritic cellsYuji Tada, Jiyang O-Wang, Yuichi Takiguchi, et al.
Pageof 14